ISPOR 2022
May 15-18, 2022
Joanna Lis, MSc, MBA, PhD
Head of Market Access
Sanofi, Poland
Joanna Lis is a Head of Market Access in Sanofi Poland and an Assistant Professor in the Department of Pharmacoeconomics at Faculty of Pharmacy at the Medical University of Warsaw (WUM). Prior to joining WUM and Sanofi, Joanna held various leadership positions in health economics area at Johnson & Johnson and Eli Lilly. Prior to joining the industry, she was an assistant professor at the Institute of Biocybernetics & Biomedical Engineering of the Polish Academy of Science (PAN) and the Medical Centre of Postgraduate Education for Physicians (CMKP).
She was the President of the ISPOR Polish Chapter (2012-2016) as well as a member of the ISPOR Central and Eastern Europe Network. In 2016-2018 she was the Director in Board of Directors International Society for Pharmacoeconomics & Outcomes Research (ISPOR). As an active member of ISPOR Polish Chapter Management Boars and ISPOR, she has been heavily involved in the ISPOR Patient Registry Special Interest Group: (ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms) and ISPOR Task Force for Transferability of Economic Evaluations across Jurisdictions. Dr. Lis has served as the Co-Chair of the Issue Panel Review Committee at ISPOR 13th Annual European Congress in Prague. Dr. Lis also co-organized the 5th Polish-Russian and Polish-Kazakh-Russian Forums on Pharmacoeconomics. She is also the co-editor of the Polish translation of ISPOR books: “Health Care Cost, Quality and Outcomes: ISPOR Book of Terms” & “Therapeutic & Diagnostic Device Outcomes Research.”
Dr. Lis is a deputy Editor-in-Chief of the Journal of Health Policy and Outcomes Research (www.jhpor.pl). She has contributed as the co-author of the Polish HTA Guidelines adopted by the Polish HTA Agency in Poland in 2009. She is a member of the experts' team of the Polish HTA Agency working on HTA Guidelines updates and HTA for medical devices Guidelines development for Poland.
She was also a leader of one of the pathways in Project on FINANCING QUALITY IN HCS: InterQuality; 7th Framework Program of EU. Dr. Lis was a member of the experts team working with HAs on New Reimbursement Law development and implementation in Poland.
Dr. Lis holds a PhD in biostatistics and computer modelling in medicine, MSc in mathematics and physics from the Jagiellonian University in Cracow and an executive MBA from Kozminski University of Business and Management in Warsaw. She has published over 70 articles. She is a co-author of various books: “Pricing: pharmaceuticals’ prices, negotiations and risk sharing agreements”, “Health Insurance Policy and Benefit Baskets: overview of the solutions” and reports: “Indirect costs in HTA: methods and recommendations”, “Risk Sharing Agreements in Poland”
She was the President of the ISPOR Polish Chapter (2012-2016) as well as a member of the ISPOR Central and Eastern Europe Network. In 2016-2018 she was the Director in Board of Directors International Society for Pharmacoeconomics & Outcomes Research (ISPOR). As an active member of ISPOR Polish Chapter Management Boars and ISPOR, she has been heavily involved in the ISPOR Patient Registry Special Interest Group: (ISPOR Taxonomy of Patient Registries: Classification, Characteristics and Terms) and ISPOR Task Force for Transferability of Economic Evaluations across Jurisdictions. Dr. Lis has served as the Co-Chair of the Issue Panel Review Committee at ISPOR 13th Annual European Congress in Prague. Dr. Lis also co-organized the 5th Polish-Russian and Polish-Kazakh-Russian Forums on Pharmacoeconomics. She is also the co-editor of the Polish translation of ISPOR books: “Health Care Cost, Quality and Outcomes: ISPOR Book of Terms” & “Therapeutic & Diagnostic Device Outcomes Research.”
Dr. Lis is a deputy Editor-in-Chief of the Journal of Health Policy and Outcomes Research (www.jhpor.pl). She has contributed as the co-author of the Polish HTA Guidelines adopted by the Polish HTA Agency in Poland in 2009. She is a member of the experts' team of the Polish HTA Agency working on HTA Guidelines updates and HTA for medical devices Guidelines development for Poland.
She was also a leader of one of the pathways in Project on FINANCING QUALITY IN HCS: InterQuality; 7th Framework Program of EU. Dr. Lis was a member of the experts team working with HAs on New Reimbursement Law development and implementation in Poland.
Dr. Lis holds a PhD in biostatistics and computer modelling in medicine, MSc in mathematics and physics from the Jagiellonian University in Cracow and an executive MBA from Kozminski University of Business and Management in Warsaw. She has published over 70 articles. She is a co-author of various books: “Pricing: pharmaceuticals’ prices, negotiations and risk sharing agreements”, “Health Insurance Policy and Benefit Baskets: overview of the solutions” and reports: “Indirect costs in HTA: methods and recommendations”, “Risk Sharing Agreements in Poland”